New Haven antibiotics developer Rib-X Pharmaceuticals hired a former senior federal drug regulator and an expert on infectious disease to shepherd its delafloxacin treatment through screening on its way to market.
Matthew A. Wikler, M.D., becomes Rib-X's chief development officer, effective April 30.
Wikler is a former deputy director of the Food and Drug Administration, which must clear Rib-X's delafloxacin, which finished Phase 2b clinical testing for acute bacterial skin and skin structure infections last December.
The drug will soon begin Phase 3 trials, authorities said.
Wikler most recently was CEO of IASO Pharma Inc., a San Diego biopharma startup also developing antibacterial and antifungal therapeutics. He also worked at several established drug and health-products firms.
Wikler's BA is from Franklin and Marshall College, his medical degree is from Temple University, and MBA from the University of Pennsylvania's Wharton School of Business.